Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy

Summary

The study of LVGN7409-201 is designed to use a bridging dose escalation to quickly establish the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as the recommended Phase 2 dose(s) (RP2D) of LVGN7409 as a single agent (monotherapy) in the treatment of locally advanced, metastatic or recurrent/refractory malignancy.

Timeline

Start

2021-09-29

Primary completion

2023-12-19

Completion

2023-12-19

Drugs

Indications